EPO Warning Enhancement Reflects Expanded FDA Adverse Event Definition
Strengthened warnings for antibody-mediated anemia in labeling for erythropoietin products reflect an expanded definition of the adverse events, FDA said Dec. 2
You may also be interested in...
Amgen is reporting four cases of pure red cell aplasia in Aranesp (darbepoetin alfa) patients
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials